Viatris will acquire the rights to Exparel and Zilretta if this acquisition goes ahead. Credit: Dragana Gordic / Shutterstock.com. California-based healthcare company Viatris has inked a billion-dollar deal to acquire Pacira BioSciences and its non-opioid pain management therapies – allowing the company to enter a market attracting growing attention amid the ongoing effects from the opioid crisis in the US. Through this deal, Viatris will pay $36.50 in cash per share for Pacira’s remaining stock

Iambic Therapeutics, a biotech that has won favour not just with investors but has also garnered support from pharma companies, is aiming for a $135m initial public offering (IPO) to fund clinical development of its AI-powered oncology pipeline. Adding financial flavour to its initial listing plans announced last month, Iambic is offering 9.4 million shares priced between $15 and $17 apiece. If the offering falls in the middle of this range, the biotech will raise $135m following deductions. Thi

Oct. 9, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it will present new data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting (ASBMR) in Boston, including results from studies of VOXZOGO® (vosoritide) in children with achondroplasia and hypochondroplasia. The company will also share data from studies of the investigational long-acting medicine BMN 333. The data include encouraging new imaging results from a post-hoc analysis of a

Oct. 11, 2026 -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for ICP-B161, a bispecific antibody targeting TL1A and IL-23p19, for the treatment of autoimmune diseases, including inflammatory bowel disease (IBD). ICP-B161 is In

With TRex Bio and Retension Pharmaceuticals through the IPO window, City Therapeutics is gearing up for its own public debut, about four months after raising a $99.5-million series B The drugmaker on Friday proposed to sell 9.7 million shares at a range of $17 to $19 apiece. At the midpoint, City would raise $175 million; if the offering prices at the high end, its market valuation could near $1 billion. Two other biotechs are waiting in the wings with City: Iambic Therapeutics, which is eyein

Oct 10, 2026 In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks UME is the leading cause of moderate and severe vision loss in patients with uveitis, posing a significant risk of blindness if left untreated The FDA has accepted Genentech’s Biologics License Application (BLA), with an approval decision expected by July 2027 October 10, 2026 -- Genentech, a member of the Roche Group (SI

Oct. 9, 2026 -- Perceptive Discovery and Nucleus RadioPharma Inc. today announced a strategic partnership to help radiopharmaceutical developers move more efficiently from early target validation through clinical manufacturing. The two companies bring together complementary capabilities that span the radiopharmaceutical development continuum. Perceptive Discovery supports sponsors with radiochemistry, preclinical models, molecular imaging, biodistribution, and dosimetry. Its scientific teams he

Medincell (Euronext: MEDCL) achieves major milestone with the announcement by its partner Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd, of the U.S. Food and Drug Administration (FDA) approval of WELTRUZA™ (olanzapine) for extended-release injectable suspension, as the first and only once-monthly subcutaneouslong-acting injectable (LAI) formulation of olanzapine for adults with schizophrenia that can help support stabilization for people living with schizophrenia.

Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost clear skin at two years and a continued favorable safety profile Oct. 9, 2026 -- Johnson & Johnson (NYSE: JNJ) today announced new two-year results from the Phase 3 ICONIC-LEADa study evaluating ICOTYDE® (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23 receptor1, in adults and pediatric pati

With an internal non-opioid program nearing approval, Viatris is picking up Pacira BioSciences for a broader pain portfolio and the associated commercial infrastructure. While awaiting a decision from the FDA on its novel non-opioid pain treatment, Viatris has agreed to buy Pacira BioSciences for $1.65 billion to accelerate its expansion into non-opioid pain therapy. Pacira sells Exparel and Zilretta, pain treatments that generated sales of $587 million and $121 million, respectively, in the s